Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Proroxan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 3/20 | 1.00 |
| ▸ | BCHE known ✓ | P06276 | 2/20 | 0.60 |
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.60 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 14/20 | 1.00 |
| ▸ | LMNA | P02545 | 10/20 | 1.00 |
| ▸ | MAPT | P10636 | 9/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 7/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 3/20 | 0.61 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Proroxan SCHEMBL635160 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAMAPTTAAR1GAA | |
| Proroxan SCHEMBL613275 | 0.99 | HTT (1.00) | ALDH1A1LMNAMAPTTAAR1GAA | |
| Proroxan SCHEMBL613276 | 0.97 | HTT (0.96) | ALDH1A1LMNAMAPTTAAR1GAA | |
| SCHEMBL29773049 | 0.93 | HTT (0.89) | ALDH1A1LMNAMAPTTAAR1GAA | |
| SCHEMBL22651536 | 0.93 | HTT (0.89) | ALDH1A1LMNAMAPTTAAR1GAA | |
| Hydrochloric Acid SCHEMBL29272586 | 0.89 | ALDH1A1 (0.81) | ALDH1A1LMNAMAPTTAAR1GAA | |
| Hydrochloric Acid SCHEMBL30948937 | 0.89 | ALDH1A1 (0.81) | ALDH1A1LMNAMAPTTAAR1GAA | |
| Hydrochloric Acid SCHEMBL29272590 | 0.89 | ALDH1A1 (0.81) | ALDH1A1LMNAMAPTTAAR1GAA | |
| Hydrochloric Acid SCHEMBL30948929 | 0.89 | ALDH1A1 (0.81) | ALDH1A1LMNAMAPTTAAR1GAA | |
| SCHEMBL22651383 | 0.88 | HTT (0.80) | ALDH1A1LMNAMAPTTAAR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3574909-B1 | POLYELECTROLYTE MULTILAYER COMPRISING SILVER FOR WOUND HEALING | IMBED BIOSCIENCES INC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20260000805-A1 | METHODS AND COMPOSITIONS FOR WOUND HEALING | IMBED BIOSCIENCES INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250375394-A1 | METHODS AND COMPOSITIONS FOR MODIFYING MUCOUS MEMBRANES | ABBOTT NICHOLAS L (US) | 2025-12-11 | — | — | US | disclosed |
| US-12409247-B2 | Methods and compositions for wound healing | IMBED BIOSCIENCES INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250221933-A1 | MICRONIZED LIPIDS | MCAL THERAPEUTICS INC. | 2025-07-10 | — | — | US | disclosed |
| US-20250221934-A1 | MICRONIZED LIPIDS | MCAL THERAPEUTICS INC. | 2025-07-10 | — | — | US | disclosed |
| US-20250205278-A1 | METHODS AND COMPOSITIONS FOR WOUND HEALING | ABBOTT NICHOLAS L (US) | 2025-06-26 | — | — | US | disclosed |
| US-12303607-B2 | Methods and compositions for modifying mucous membranes | ABBOTT NICHOLAS L (US) | 2025-05-20 | — | — | US | disclosed |
| US-12214079-B2 | Micronized lipids | MCAL THERAPEUTICS INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-12214080-B2 | Micronized lipids | MCAL THERAPEUTICS INC. (US) | 2025-02-04 | — | — | US | disclosed |
| EP-4289910-A2 | METHODS AND COMPOSITIONS FOR WOUND HEALING | Imbed Biosciences, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| US-11793832-B2 | Methods and compositions for wound healing | ABBOTT NICHOLAS L (US) | 2023-10-24 | — | — | US | disclosed |
| EP-3490622-B1 | METHODS AND COMPOSITIONS FOR WOUND HEALING | IMBED BIOSCIENCES INC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-11712423-B2 | Methods and compositions for modifying mucous membranes | ABBOTT NICHOLAS L (US) | 2023-08-01 | — | — | US | disclosed |
| WO-2023064443-A1 | ANTIMICROBIAL COMPOSITIONS | CORNELL UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
| US-11554194-B2 | Methods and compositions for wound healing | IMBED BIOSCIENCES INC. (US) | 2023-01-17 | — | — | US | disclosed |
| US-20220362154-A1 | MICRONIZED LIPIDS | MCAL THERAPEUTICS INC. | 2022-11-17 | — | — | US | disclosed |
| US-20220362155-A1 | MICRONIZED LIPIDS | MCAL THERAPEUTICS INC. | 2022-11-17 | — | — | US | disclosed |
| EP-3995158-A1 | METHODS AND COMPOSITIONS FOR WOUND HEALING | Imbed Biosciences, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| US-11246873-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220362155-A1 | MICRONIZED LIPIDS | SGMS1, SGMS2, MGLL | GAA 3874/4885BCHE 4301/4885ACHE 4485/4885 |
| US-20260000805-A1 | METHODS AND COMPOSITIONS FOR WOUND HEALING | PCNA, ARG1, PLOD3 | GAA 4462/4885BCHE 2754/4885ACHE 1705/4885 |
| US-20250221933-A1 | MICRONIZED LIPIDS | SGMS1, SGMS2, MGLL | GAA 3874/4885BCHE 4301/4885ACHE 4485/4885 |
| US-20220362154-A1 | MICRONIZED LIPIDS | SGMS1, SGMS2, MGLL | GAA 3874/4885BCHE 4301/4885ACHE 4485/4885 |
| US-20250221934-A1 | MICRONIZED LIPIDS | SGMS1, SGMS2, MGLL | GAA 3874/4885BCHE 4301/4885ACHE 4485/4885 |
| US-12214079-B2 | Micronized lipids | SGMS1, SGMS2, MGLL | GAA 3874/4885BCHE 4301/4885ACHE 4485/4885 |
| US-12214080-B2 | Micronized lipids | SGMS1, SGMS2, MGLL | GAA 3874/4885BCHE 4301/4885ACHE 4485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.